Care Together Seed Funding Evaluation

Open

Buyers

Value

£24,995

Classifications

  • Research and development services and related consultancy services
  • Health and social work services

Tags

  • tender

Submission Deadline

2 weeks from now

Published

40 minutes ago

Description

Cambridgeshire County Council is commissioning an independent, proportionate evaluation of the seed-funded element of the Care Together programme. Care Together has several components, including community-led projects supported through small grants and wider activity designed to strengthen local support for older people.
This evaluation focuses on the community-led projects that received seed funding. The evaluation will provide a high-level assessment of delivery and early outcomes across all district areas, supported by a small number of case studies and light-touch engagement with partners, participants and community organisations. It will explore the programme's contribution to prevention and early help, identify key learning, and highlight what works well across different community settings.
Findings will inform future commissioning and support the development of a practical evaluation toolkit to guide monitoring and assessment for the 2026/27 Care Together funding round.

Similar Contracts

Open

ASC25078 Direct Payment Support

The Council is seeking a supplier to deliver Direct Payment Support across two distinct Lots. A supplier can be awarded either a single Lot or both Lots o Lot 1 – Direct Payments Strategic Support Partner o Lot 2 – Direct Payment Finance Partner The Direct Payments Strategic Support Partner would be required to deliver strategic support to promote the growth of direct payments across Worcestershire and find suitable services to meet the needs of direct payment recipients. As part of Lot 1 the Strategic Support Partner would act as a micro brokerage service for Direct Payment recipients, advising what may be available to them in their area, both paid for and free services that might be available in the Voluntary Community Sector (VCS). The Supplier would also be required to advise social work staff where required. This wider remit could lead to closer working with the Communities Directorate, social prescribers and public health initiatives, supporting the Council to deliver the right service at the right time and the right price. There is evidence that this has worked well in other local authorities, especially with voluntary or service-user-led organisations. It is likely that the VCS will benefit from this approach as they have all the skills available to support people to maximise the potential of direct payments. As part of Lot 2, the Direct Payment Finance Partner would deliver a financial management service with elements within the contract covering support for the payments, including managed accounts and payroll for Personal Assistants (PAs). The Finance Partner would also be operating managed accounts on WCC’s behalf in line with new approval process and are required to employ PA’s to deliver cost-effective services.

Katy Reed

Published 41 minutes ago
Open

Scientific Consultant for Medicines Discovery Catapult

Medicines Discovery Catapult (MDC) is an independent, not-for-profit innovation centre for drug discovery and part of the Catapult Network established by Innovate UK. MDC's vision is to reshape drug discovery for patient benefit by transforming great UK science into better treatments through partnership. It supports drug discovery innovators by making world-class expertise, facilities, complex technologies, and advanced analytics accessible to enable successful medicines discovery. MDC develops pioneering, impactful R&D collaborations across biotech, academia, technology companies, charities, and global pharma. It brings these communities together in active, focused national programmes that target high-risk areas of patient need. This requirement originates from the Partnership Team at Medicines Discovery Catapult (MDC), which includes national programmes across neuroscience and infection, virtual R&D, and complex medicine. The team plays a central role in enabling and accelerating UK drug discovery by identifying unmet needs, supporting ecosystem coordination, and helping to navigate the scientific and translational complexities of areas such as diseases of the brain. To fulfil its role effectively, the team must remain consistently informed about recent scientific developments, innovation opportunities, and areas of commercial promise. This enables MDC to identify and shape collaborative initiatives, support investment cases, and build strategies aligned to evolving national and global health priorities. The current emphasis has been on neuroscience, particularly neurodegenerative diseases, mental health, and drug discovery and delivery. Previous work has included: • A landscape mapping exercise to inform the strategy for the Dementia Goals Programme, providing a foundational view of the UK's capabilities, gaps, and opportunities; • Exploration of emerging scientific trends and innovation gaps within mental health, supporting the work of the Psychiatry Consortium; • Early-stage analysis on cross-cutting opportunities within complex medicine. Building on this initial work, MDC now seeks to expand the scope and focus of the landscape activity to include: • Deeper insights into priority areas aligned to the Partnership Team's strategic objectives; • A clearer understanding of challenges such as blood-brain barrier (BBB) penetration and the development of novel Central Nervous System drug modalities; • Identification of translational and commercial opportunities across neuroscience and beyond (e.g., infectious diseases). MDC requires a consultant to: • Provide ongoing scientific and strategic intelligence relevant to current and future areas of focus and interest such as neuroscience, infection, CNS drug delivery, etc. • Identify translational and commercial opportunities through horizon scanning and landscape analysis in defined scientific areas. • Support development of investment cases and programme design by synthesising internal and external data sources. • Produce materials including presentations, written briefs, dashboards, and updates for internal and external stakeholders. Deliverables would be specific for each project, but it is expected that they could include: • Monthly briefings summarising relevant scientific, policy, and/or commercial developments (oral or written). • At least one deep-dive landscape output (e.g., dashboard, short report or slide deck) per quarter, focused on agreed priority themes (e.g., BBB, emerging modalities, patient stratification). • Ad hoc input to internal programme development and stakeholder materials (e.g., funder presentations, project design). The supplier must have a proven track record of delivering high quality technical writing, with strong communication skills. A minimum of 5 years' experience in technical or scientific writing, with demonstrable experience in life sciences. Access to proprietary databases to access the relevant datasets useful for the specific projects (including OpenAlex, Europe PMC, PubMed, CrossRef, Dimensions, Lens.org (patents), ClinicalTrials.gov, WHO ICTRP, NICE Evidence). Expertise in the use of AI and language models to automate and classify data retrieval and apply thematic analyses Proven ability to synthesise scientific and commercial insights for strategic use. Previously work in areas relevant to MDC strategic mission.

Katy Reed

Published 2 hours ago

AI Bid Assistant

Our AI-powered tool to help you create winning bids is coming soon!

View Contract Source Save Contract

Timeline active

Publish
Bid
Evaluate
Award
Complete